The identification of eosinophilic pathways and the IL-5 axis, integrin signaling, and exosome release offers new targets for developing novel treatments aimed at reducing airway inflammation and remodeling by improving outcomes in patients with severe asthma. The gene discussed is IL5; the disease is asthma.